Shionogi Deal History & Licensing Activity
Shionogi is a mid-size pharma headquartered in Japan. Over the past three years, Shionogi has been involved in 4 licensing and acquisition transactions, with a primary focus on Small Molecules (5 deals). The company currently has 20 active clinical trials, primarily in Infectious.
Deals (12mo)
3
Active Trials
20
Top Modality
Small Molecules
Focus Area
Infectious
Shionogi Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Shionogi in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Shionogi-Apnimed Sleep Science (SASS) joint venture stake | Apnimed | Small Molecules | Phase 2 | acquisition | Mar 26, 2026 |
| RADICAVA | Mitsubishi Tanabe Pharma (originator) | Small Molecules | Approved | acquisition | Dec 22, 2025 |
| BV500 | Shionogi & Co. | Small Molecules | Discovery | option | Dec 11, 2025 |
Shionogi Pipeline Focus
Therapeutic areas and modalities where Shionogi is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Shionogi Strategic Signals
Key indicators of Shionogi's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Shionogi Clinical Pipeline
Shionogi has 20 active clinical trials across 6 development phases.
1
Phase 4
1
Not Applicable
5
Phase 1
2
Phase 1/2
8
Phase 2
3
Phase 3
See How Your Asset Matches Shionogi's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Infectious assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Shionogi Licensing & Deal Activity
Shionogi is a mid-size pharma company based in Japan that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Shionogi ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Shionogi include Infectious (6 deals and trials), Neurology (4 deals and trials), Rare Disease (4 deals and trials), and Infectious Disease (2 deals and trials). In terms of modality, Shionogi has shown particular interest in small molecules, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Shionogi and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Shionogi's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.